These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38847539)

  • 1. Development of a vesicular stomatitis virus pseudotyped with herpes B virus glycoproteins and its application in a neutralizing antibody detection assay.
    Kinoshita H; Yamada S; Ogawa T; Nguyen PHA; Harada S; Kawahara M; Ishijima K; Maeda K; Ebihara H; Fukushi S
    mBio; 2024 Jul; 15(7):e0109224. PubMed ID: 38847539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Vesicular Stomatitis Virus Pseudotypes Bearing Essential Entry Glycoproteins gB, gD, gH, and gL of Herpes Simplex Virus 1.
    Rogalin HB; Heldwein EE
    J Virol; 2016 Nov; 90(22):10321-10328. PubMed ID: 27605677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of the Four Essential Entry Glycoproteins to HSV-1 Tropism and the Selection of Entry Routes.
    Hilterbrand AT; Daly RE; Heldwein EE
    mBio; 2021 Mar; 12(2):. PubMed ID: 33653890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
    Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
    Komala Sari T; Gianopulos KA; Nicola AV
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV Glycoproteins.
    Lay Mendoza MF; Acciani MD; Levit CN; Santa Maria C; Brindley MA
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33348746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
    Zhu Z; Han Y; Gong M; Sun B; Zhang R; Ding Q
    J Virol; 2024 May; 98(5):e0195723. PubMed ID: 38557247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of herpes simplex virus gB-induced cell-cell fusion by mutant forms of gH/gL in the absence of gD and cellular receptors.
    Atanasiu D; Cairns TM; Whitbeck JC; Saw WT; Rao S; Eisenberg RJ; Cohen GH
    mBio; 2013 Feb; 4(2):. PubMed ID: 23443004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Antibodies and Mutants To Localize the Presumptive gH/gL Binding Site on Herpes Simplex Virus gD.
    Atanasiu D; Saw WT; Lazear E; Whitbeck JC; Cairns TM; Lou H; Eisenberg RJ; Cohen GH
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30282715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.
    Lee SS; Phy K; Peden K; Sheng-Fowler L
    Vaccine; 2017 Oct; 35(41):5481-5486. PubMed ID: 28427845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins.
    Fukushi S; Watanabe R; Taguchi F
    Methods Mol Biol; 2008; 454():331-8. PubMed ID: 19057867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system.
    Suda Y; Fukushi S; Tani H; Murakami S; Saijo M; Horimoto T; Shimojima M
    Arch Virol; 2016 Jun; 161(6):1447-54. PubMed ID: 26935918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes B virus utilizes human nectin-1 but not HVEM or PILRα for cell-cell fusion and virus entry.
    Fan Q; Amen M; Harden M; Severini A; Griffiths A; Longnecker R
    J Virol; 2012 Apr; 86(8):4468-76. PubMed ID: 22345445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.
    Hook LM; Huang J; Jiang M; Hodinka R; Friedman HM
    J Virol; 2008 Jul; 82(14):6935-41. PubMed ID: 18480440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat-containing G protein-coupled receptor 4 facilitates vesicular stomatitis virus infection by binding vesicular stomatitis virus glycoprotein.
    Zhang N; Huang H; Tan B; Wei Y; Xiong Q; Yan Y; Hou L; Wu N; Siwko S; Cimarelli A; Xu J; Han H; Qian M; Liu M; Du B
    J Biol Chem; 2017 Oct; 292(40):16527-16538. PubMed ID: 28842478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.
    Konduru K; Shurtleff AC; Bavari S; Kaplan G
    J Virol Methods; 2018 Apr; 254():1-7. PubMed ID: 29355585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host.
    Martinez I; Barrera JC; Rodriguez LL; Wertz GW
    Vaccine; 2004 Sep; 22(29-30):4035-43. PubMed ID: 15364454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
    Fukushi S; Mizutani T; Saijo M; Kurane I; Taguchi F; Tashiro M; Morikawa S
    J Med Virol; 2006 Dec; 78(12):1509-12. PubMed ID: 17063504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines.
    Whitt MA
    J Virol Methods; 2010 Nov; 169(2):365-74. PubMed ID: 20709108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.